Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China flag China · Delayed Price · Currency is CNY
6.38
-0.50 (-7.27%)
Jul 29, 2026, 3:00 PM CST

SHA:603567 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-1,622-1,367438.22472.74185.44332.1
Depreciation & Amortization
174.59174.59144.06190.44169137.1
Other Amortization
17.5517.557.1710.7512.1817.78
Loss (Gain) From Sale of Assets
0.610.611.680.26-39.520.89
Asset Writedown & Restructuring Costs
14.7214.720.633.911.470.3
Loss (Gain) From Sale of Investments
11.9511.959.69-464.47-24.73-242.67
Provision & Write-off of Bad Debts
299.72299.72117.823.84-29.844.34
Other Operating Activities
1,463877.14212.67233.95162.63211.71
Change in Accounts Receivable
-947.8-947.8304.34-891.41107.18-1,233
Change in Inventory
-177.03-177.03-850.83282.66-270.89381.02
Change in Accounts Payable
1,7281,728-214.5-277.49-521.86-74.84
Change in Other Net Operating Assets
----0.62-0.87
Operating Cash Flow
652.58322.1164.31-478.24-326.79-433.94
Operating Cash Flow Growth
71516.35%96.03%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-50.58-68.52-189.15-95.14-404.27-448.63
Sale of Property, Plant & Equipment
2.662.38118.2129.450.643.7
Cash Acquisitions
-----17.51-
Divestitures
--094.87369.74373
Investment in Securities
-490.14-530.87-48.86-53222.9-757.24
Other Investing Activities
--13.79100.25112.44407.91
Investing Cash Flow
-538.06-597.01-106.02176.43283.93-421.26

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-1,4151,7902,6551,680860
Total Debt Issued
1,4441,4151,7902,6551,680860
Long-Term Debt Repaid
--1,835-1,880-2,441-1,724-1,138
Total Debt Repaid
-2,007-1,835-1,880-2,441-1,724-1,138
Net Debt Issued (Repaid)
-562.88-420.38-90.19214.05-44.4-278.12
Issuance of Common Stock
---219.68-1,228
Repurchase of Common Stock
-----29.99-
Common Dividends Paid
-274.95-276.56-324.28-158.28-243.55-143.73
Other Financing Activities
-2.45-1.57-39.7490.24-101-8.7
Financing Cash Flow
-840.28-698.51-454.16765.69-418.94797.46

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-725.76-973.42-395.88463.87-461.81-57.74

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
602253.57-24.84-573.38-731.07-882.57
Free Cash Flow Growth
------
Free Cash Flow Margin
118.05%31.80%-0.92%-18.27%-17.35%-21.39%
Free Cash Flow Per Share
0.640.27-0.03-0.61-0.78-1.02
Levered Free Cash Flow
1,030631.19-293.68-746.75-404.69-881.7
Unlevered Free Cash Flow
1,115718.06-208-662.12-318.01-791.21

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
76.81124.51316.2380.65201.36429.61
Change in Working Capital
292.34292.34-767.62-929.67-763.46-935.49